Information Provided By:
Fly News Breaks for August 31, 2016
AGN, SHPG
Aug 31, 2016 | 07:07 EDT
After hosting meetings with management, Jefferies analyst David Steinberg believes Shire (SHPG) is making "all the right moves" to make its dry eye drug Xiidra a potential $2B peak product in the U.S. Shire's Xiidra is competing with Allergan's (AGN) $1.4B dry eye drug Restasis, Steinberg tells investors in a research note. The analyst does not think Shire will have any problem exceeding the drug's consensus sales forecast of $200M for next year. He keeps a Buy rating on the shares with a $262 price target.
News For SHPG;AGN From the Last 2 Days
There are no results for your query SHPG;AGN